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Abstract
Biopharmaceutical companies are focusing on operational efficiency more than ever before due
to cost pressures, generic competition, complex pricing, regulations, and globalization. Due to
the low probabilities of success of drug development and achieving market penetration, it is
critical for a company to optimize the sizing of a manufacturing facility to achieve maximum
capacity utilization while avoiding or minimizing non-productive, idle capacity. In order to
achieve high manufacturing efficiency and minimize capital risks, many firms elect to outsource
various phases of the drug development value chain.
This thesis investigates the major drivers for vertical integration and outsourcing in the
biopharmaceutical industry. This work examines outsourcing and vertical integration decisions
including their financial, organizational, and strategic effects on the organization. It presents a
methodology and framework for strategic sourcing decisions and includes a set of quantitative
tools for assessing outsourcing options and guidelines for selecting, implementing, and managing
relationships with contract manufacturers. These frameworks are applied to case studies
conducted at the Genzyme Corporation. The strategic sourcing decisions tools developed in this
work are highly customizable and can be adopted by other companies in the biopharmaceutical
industry.
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Chapter 1: Introduction
Many biopharmaceutical companies embrace outsourcing as an essential part of their corporate
strategy, whereas, other firms view outsourcing as a last resort option and elect to pursue vertical
integration. In the early 1980s, federal regulations were enacted that required significant due
diligence and quality control of clinical trials and thus many biopharmaceutical companies
elected to outsource the heavily regulated clinical trial process to contract research
organizations. Large biopharmaceutical corporations now typically use contract manufacturers
and research organizations to satisfy short-term capacity demands. This researcher believes that
the typical biopharmaceutical firm needs to perform a comprehensive assessment of their tactical
capacity-driven outsourcing option relative to their overall strategic planning for product
development and marketing. The "make versus buy" decision is not one to be taken lightly and
should be fully evaluated prior to implementation. This thesis develops a framework for the
make versus buy decision that is specifically applicable to the biopharmaceutical industry and
applies it to case studies conducted at Genzyme Corporation.
The following discussion provides the context for strategic sourcing in the biopharmaceutical
industry. The company studied, Genzyme Corporation, together with ILEX Oncology are
introduced along with the project goals, motivation, and methodology.
1.1 GENZYME CORPORATION
Genzyme is a global biotechnology company committed to developing drugs for unmet medical
needs. Genzyme has approximately 7,000 employees and annual revenues of over $2 billion in
20041. Their products and services are focused on rare genetic disorders, kidney disease,
cancer, orthopaedics, transplant and immune disease, and diagnostic testing. Genzyme has 14
manufacturing sites (of which 10 are operated under GMP) along with numerous office locations
spanning the globe. They have 10 major marketed therapeutic products in the biologic and
chemical arenas. Genzyme is most known for its commitment to treating rare genetic disorders
through the development of biologic drugs. These drugs, categorized as orphan drugs because
Genzyme Corporation website: http://www.genzyme.com
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they treat a disease affecting fewer than 200,000 Americans 2, represent upwards of 50% of
Genzyme's annual revenue in 2003. Figure 1-1 depicts the contribution of Genzyme's major
products to their annual revenue in 2004 of $2.2 billion.
Genzyme Revenue by Product
Annual Revenue = $2.2 Billion
Other Small
5% Molecule and
Diagnostics & Polymer
Genetics (Renagel@)
6%
Biosurgery
14%
Transplant
3%
Thyrogen@ 46%
3%
Fabrazyme@ Cerezyme@
5%
Figure 1-1: Genzyme Product Portfolio - Contribution to Annual Revenue in 2004
The greatest potential for growth and diversification at Genzyme lies in the area of developing
small molecule and polymer (compounds like Renagel®) drugs. Renagel is a synthetic polymer
product used in the reduction of serum phosphorus in hemodialysis patients. Small molecule and
polymer drugs are designed to block key chemical pathways related to the disease mechanisms
within the body. The drugs are typically provided in oral dosage form (existing either as
capsules, tablets, liquids, or suspensions).
Of the 14 Genzyme manufacturing sites, two were analyzed for the purpose of this thesis:
Haverhill, UK, and Waterford, Ireland. Haverhill produces the bulk active ingredient selevamer
which is used for the Renagel product. In addition, Haverhill is equipped with a pilot scale GMP
2 FDA website: http://www.fda.gov/cder/handbook/orphan.htm
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facility for producing other bulk ingredients that are used in the production of a variety of other
drug products. At the Waterford location, various production activities related to Renagel occur
including tableting, packaging and shipping world-wide. Waterford is also equipped with a
development facility that is utilized to test new procedures and equipment modifications related
to small scale GMP tableting operations.
1.2 ILEX ONCOLOGY
ILEX Oncology, a cancer drug development company, was acquired by Genzyme in December
2004. The acquisition strengthened Genzyme's oncology business by adding the commercial
drug Campath* indicated for the treatment of B-chronic lymphocytic leukemia (B-CLL) in
patients that have been treated with alkylating agents and who have failed fludarabine therapy.
TMCampath, as well as a strong pipeline with the product CLOLAR , for the treatment of children
with refractory or relapsed acute lymphoblastic leukemia (ALL) nearing approval and another
drug in Phase 2 (ILX-65 1) of clinical trials, were added to Genzyme's product portfolio via the
acquisition. ILX-651 is a synthetic dolastatin analog that is currently being studied in phase II
metastatic melanoma, non-small cell lung cancer and prostate cancer clinical trials. Genzyme's
oncology pipeline, including those drugs obtained via the acquisition of ILEX Oncology is
shown in Figure 1-2.
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Genzyme Oncology Pipeline
Research > Preclinical >> Clinical Trials >>> Postmarketing
0NCL0G
CAMPATH . Chronic Lymphocytic Leukemia (CLL)
CLOLAR - Acute Lymphocytic Leukemia (ALL)
CAMPATH - Multiple Sclerosis (MS)
ILX651 Melanoma. Lung Cancer. Prostate Cancer
CAMPATH - Non-Hodgkin's Lymphoma (NHL)
Carabine - Solid Tumors
DENSPM . Liver Cancer
GC1008 - Solid Tumors
T EMS Antibodies - Solid Tumors
Figure 1-2: Genzyme's Oncology Pipeline3
'>2%
Like many drug development companies, prior to the acquisition, ILEX outsourced production of
their drugs. Genzyme was faced with the strategic sourcing decision of whether to continue to
outsource manufacturing of ILEX's product line post-acquisition, or alternatively choose the
"make" in-house option, which would involve significant capital expenditure to accommodate a
full facility build.
1.3 PROJECT MOTIVATION AND SETTING
Genzyme Corporation has 14 manufacturing sites for its biologic, small molecule, and polymer
based drugs. Genzyme, widely known for its biologic drugs, is expanding its presence in the
small molecule and polymer drug market. The small molecule and polymer product line
currently comprises approximately 18% of Genzyme's revenue, and there are tremendous growth
opportunities in this area.
3 Genzyme Corporation 2003 Annual Report available from http://www.genzyme.com
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As Genzyme continues to grow, organically and via acquisitions, it needs to evaluate the make
versus buy decision. Genzyme firmly believes in vertical integration (initially this was due the
fact that very few contract manufacturers (CMOs) had the capabilities to manufacture biologic
compounds). However, in the small molecule arena there is an excess of CMO capabilities and
Genzyme needed to reassess its make versus buy decisions. This thesis focuses on developing a
framework for analyzing the make versus buy option for development, clinical, and commercial
production of API (Active Pharmaceutical Ingredient) and DP (finished drug product) for small
molecule and polymer based drugs at Genzyme.
To develop the proposed framework to assist in the make versus buy decisions, the researcher
selected a case study involving the encapsulation process; in particular, the equipment
requirements, facility requirements, and industry trends were evaluated. The encapsulation
process was selected as the case study because this process was identified as a gap by the
researcher and others at Genzyme.
Genzyme recently announced a merger with ILEX Oncology, which brings cytotoxic and highly
potent drugs into Genzyme's product mix. This project involved developing a manufacturing
strategy for high potency drugs and assessing the cost-benefit of outsourcing the production of
these compounds both at the clinical trial and commercial production phases. The cost-benefit
analysis included an assessment of the typical direct manufacturing costs as well as the indirect
costs associated with the mitigation of health and environmental (containment and isolation
equipment) hazards related to producing high potency drugs.
1.4 PROJECT GoALs AND OBJECTIVE
The principal objective of this thesis was to provide Genzyme management with a framework to
assist in determining what technologies and capabilities Genzyme should bring in-house (the
make option) and which should be outsourced (the buy option) for both development scale
production of API (active pharmaceutical ingredient) and commercial scale production of DP
(finished drug product) for small molecule and polymer based drugs. This was accomplished by
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analyzing the gaps in Genzyme's development capabilities and the technology needs for a
portion of their incoming small molecule and polymer based drug pipeline. The secondary
objectives of this thesis included:
1. Perform a requirements analysis for the incoming pipeline of a portion of Genzyme's
small-molecule and polymer based drugs.
2. Perform a GAP analysis of Genzyme's manufacturing capabilities for clinical and
early stage commercial production for the DP production at Genzyme's Waterford,
Ireland facility and API production at Genzyme's Haverhill, England facility.
3. Analyze the costs-benefits and timing considerations of bringing equipment in-house
versus outsourcing during clinical and pilot plant manufacturing.
4. Develop a methodology for analyzing the strategy of bringing on new products and
new technologies by assessing the product approval timeline, market forecast, costs
and requirements for production, probability of success, ramp rate and product life
cycle.
5. Assess the high potency market, ILEX's outsourcing strategy, manufacturing
requirements, and contract manufacturing capabilities to determine if Genzyme
should manufacture high potency compounds in-house.
1.5 APPROACH AND METHODOLOGY
In order to develop a framework for determining what production capabilities Genzyme should
bring in-house for small molecule and polymer based drugs the researcher undertook an
evaluation which incorporated the following analyses:
. Analyzed Genzyme's and ILEX's current pipeline of small molecule and polymer based
drugs, incorporating probabilities of success.
. Performed a GAP analysis of Genzyme's manufacturing capabilities for clinical and early
stage commercial production of small-molecule and polymer-based drugs.
o GAP analysis to determine the knowledge and manufacturing gaps that exist for
both the production of API and DP.
o Production and research facilities that were studied included:
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- Waterford, Ireland (Genzyme's DP site)
- Haverhill, England (Genzyme's API site)
- Waltham, Massachusetts (Genzyme's R&D site)
- San Antonio, Texas (ILEX's site)
. Assessment of Genzyme's current equipment, capacity and supply chain issues to
determine any potential manufacturing constraints with regard to capacity limitations,
supply and demand effects, and shortages.
. Capacity and utilization calculations of manufacturing equipment and associated quality
assurance and containment/isolation equipment.
. NPV and IRR calculations of site build.
. Benchmarking of industry best practices for manufacturing of biopharmaceutical
products, with particular attention to high potency products.
. Financial and strategic assessment of facility locations in Ireland, England, and US with
regards to tax incentives, equipment and employee capabilities, and supply chain.
* Competitive analysis of vertical integration strategies and CMO (contract manufacturing
organization) usage.
. Assessment of CMO capabilities.
1.6 TERMINOLOGY
Strategic sourcing decisions are often called the "make versus buy" decision. Make versus buy
refers to the decision of a company to perform a function in-house using already existing internal
resources or adding new capabilities in order to be able to conduct the function in-house. The
term "buy" refers to outsourcing a function to an external source.
In the biopharmaceutical industry, outsourcing to a third party involves using contract service
organizations (CSOs). The term CSO includes contract research organizations (CROs), contract
manufacturing organizations (CMOs), site management organizations (SMOs), and other outside
contract organizations that support the biopharmaceutical industry.
The production of pharmaceutical drugs involves formulating the active pharmaceutical
ingredient (API) or bulk product and final drug product (DP), which is in the finished dosage
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form. An active pharmaceutical ingredient (API) is a chemical entity (or mixture) intended to be
used in the manufacturing of a drug product, that when formulated, becomes the active
ingredient of the drug product. The active ingredient of a drug is the chemical entity that causes
the therapeutic response. The drug product is composed of both active ingredient and excipients.
Excipients are typically inert substances that are used in drug products to assist in delivery or as
fillers.
1.7 THESIS OVERVIEW
This thesis develops a framework for the make versus buy decision that is unique to the
biopharmaceutical industry. The decision to build or add to a facility often has to be made when
a drug is in the early phases of the clinical trial process, when the probability of success is at best
50%. This thesis suggests a framework to assist in the strategic sourcing decision process and
applies it to two case studies conducted at Genzyme. The format of the thesis is as follows:
Chapter 1: Introduction
Chapter 1 provides the context for strategic sourcing in the biopharmaceutical industry. The
company studied, Genzyme Corporation, together with ILEX Oncology are introduced along
with the project goals, motivation, and methodology.
Chapter 2: Manufacturing Strategies in the Biopharmaceutical Industry
Chapter 2 discusses the manufacturing environment in the biopharmaceutical industry. It
describes the value chain of the industry and the manufacturing strategies that various
biopharmaceutical firms have utilized to compete within the industry.
Chapter 3: Strategic Sourcing Decision Tools
Chapter 3 details the strategic sourcing process and includes an overview of vertical integration
strategies. This chapter highlights the major factors to consider when deciding to outsource or
perform in-house.
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Chapter 4: Application of Strategic Sourcing Frameworks to Encapsulation
Chapter 4 is a case study application of the strategic sourcing frameworks that were developed to
assist Genzyme in the make versus buy decision. It details the development capability for
encapsulation of a drug and applies the make versus buy framework.
Chapter 5: Application of Strategic Sourcing Frameworks to High Potency Compound
Manufacturing
Chapter 5 is an additional case study of the strategic sourcing framework related to the make
versus buy decision for the ILEX product line which was acquired by Genzyme This chapter
details the concerns associated with the high potency products that were being considered to be
manufactured in-house and based upon the framework defines a manufacturing strategy for this
product line.
Chapter 6: Conclusions, Recommendations and Future Activities
Chapter 6 presents the researcher's conclusions, recommendations, and proposed future
activities. It summarizes the key lessons learned with regards to strategic sourcing in the
biopharmaceutical industry. Recommendations for further applications of the strategic sourcing
framework are discussed. Proposed follow-on future activities related to Genzyme's vertical
integration strategy are presented.
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Chapter 2: Manufacturing Strategies in the Biopharmaceutical
Industry
2.1 CHAPTER OVERVIEW
This chapter describes the biopharmaceutical industry and its associated value chain. Strategic
sourcing decisions within this industry are discussed in detail and a methodology for selecting
and assessing contract manufacturers is presented. Also, a comparison of the manufacturing
strategies that various biopharmaceutical firms utilize to compete in the marketplace is presented
together with an evaluation of their manufacturing sourcing strategies.
2.2 BIOPHARMACEUTICAL INDUSTRY
The biopharmaceutical industry is highly regulated, has very large barriers to entry, and offers
the potential of high monetary rewards within an extremely high risk market. The development
time for a drug is estimated to be at least 10 years with expenditures of $800 million to bring a
product to market4. It is estimated that only 1 in 10,000 chemicals that undergo evaluation ever
reach the market as a pharmaceutical product. This high failure rate causes many pharmaceutical
manufacturers to develop a very strong and diverse R&D focus across many therapeutic areas.
The high cost of drug development coupled with the high cost associated with development
failures results in a strategy of having multiple drugs in the pipeline. This high cost and high risk
market also leads to the "blockbuster" market paradigm in which markets tend to support the
high price of drugs. A blockbuster drug typically generates in excess of $1 billion in annual
revenues and is the major revenue source for large pharmaceutical firms. This large revenue
stream is often obtained through moderate pricing of a drug that serves a very large patient
4 DiMasi, Joseph A.; Hansen, Ronald W.; Grabowski, Henry G. "The Price of Innovation: New Estimates of Drug
Development Costs," Journal of Health Economics, 22 (2003) 151-185
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population. Of the biopharmaceutical companies, only Genentech and Amgen have blockbuster
drugs in their product portfolio.
Blockbuster products are the minority of the overall product line yet they drive the revenue and
finance the R&D and failures of the other products. Current estimates show that pharmaceutical
products that presently generate revenues in excess of $100 billion dollars will have their patents
expire in 20055; then the generic pharmaceutical manufacturers will be able to capture a
predominant measure of the number of prescriptions written. The generic market poses a
significant threat to the pharmaceutical companies, specifically to the income stream generated
by these blockbuster drugs as they come off patent. The patent expiration risk, coupled with the
aforementioned market tendencies lead to pharmaceutical strategies of in-licensing, mergers and
acquisitions to grow their pipelines.
2.2.1 Biopharmaceutical Industry Value Chain
There are four major stages in the biopharmaceutical value chain: research and development,
clinical testing, manufacturing, and marketing and sales. Figure 2-1 depicts the value chain for
the biopharmaceutical industry.
Research Discovery Development Product launchPre- Phase Phae Pha Drug
Target Lead Identification clinical I i III registration Manu. Marketin
identification and optimization Formulation facture Phase IV
Tzrgts Lead NDA
Figure 2-1: Value Chain with Milestones for Biologics and Pharmaceuticals
6
Due to regulations, all drugs undergo clinical testing prior to entering the market. Clinical
testing typically follows the following stages:
5 Reuters Business Insight. "Strategic Intelligence: The Top 12 Pharmaceutical Companies." November 2001.
6 MIT Sloan BioPharma Business Club. "The Sloan Biopharma Business Club's Industry Fact Pack." October 2002.
Available from http://web.mit.edu/biopharma/resources/biopharma-factpack-vfall0
2
.pdf
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o Pre-Clinical: The drug is studied in-vivo on animals or in-vitro to determine its safety
profile prior to testing in humans.
o Phase I: The drug is tested on a small group of healthy patients to establish the effects
of the new drug in humans. These studies are designed to determine such things as
the drug's toxicity, metabolism, absorption, and distribution.
o Phase II: After safety has been established through successful Phase I trials, the drug
is tested for safety and efficacy in a slightly larger patient population of patients who
have the disorder that the drug was developed for.
o Phase III: The drug is administered to a large patient population to verify the safety
and efficacy as well as the optimum dosage regimens of the drug. Often, the new
drug is compared with the gold standard therapy that is currently used for treating the
disorder. The results from this trial are often included in the package insert and
labels.
o Phase IV: These studies are conducted post-approval by the FDA to further study
adverse effects, study additional patient populations, or compare the drug to a
competitor.
After the drug has passed through the clinical trial stages, an NDA (New Drug Application) is
filed and if the FDA approves the drug for safety and efficacy, it can be marketed and sold.
2.2.2 Probability of Success
The biopharmaceutical industry is one that operates in a high risk, high reward environment.
Developing a new drug can take over ten years and cost hundreds of millions of dollars. For
each drug that makes it to market, there are thousands that fail somewhere in the development
cycle. Those drugs that are successful, however, have the potential to generate billions of dollars
in revenue. The leading pharmaceutical companies have all taken different strategies to manage
the time and capital risks, maintain a consistent revenue stream, and increase their chances of
developing the next high-value "blockbuster" drug. Figure 2-2 highlights the probability of
success for drugs passing each of the clinical testing hurdles. As shown, the probability of a
-21 -
drug being approved and launched is
years) from inception to launch7.
only 10% and takes between 4 and 23 years (on average 10
Rate of time Mean time Probability of
(years) (years) Success
R&D 0.5-6.5 4.5 50%
Project start to IND
filing
Clinical 0.5-1.5 1 71%
Phase I clinical
Clinical 1.0-5.0 2 45%
Phase 11 clinical
Clinical 1.0-5.0 3 86%
Phase IIl clinical
Market 1.0-5.0 2.5 73%
FDA review of NDA
& launch
TOTAL 4.0-23.0 13 10%
Figure 2-2: Probability of Success for Pharmaceuticals8
2.3 MANUFACTURING IN A REGULATED ENVIRONMENT
Like the nuclear power industry and commercial aviation, the biopharmaceutical industry is a
highly regulated environment. This regulatory environment has high costs associated with
implementation and obedience. The implications of these regulations have led many in the
biopharmaceutical industry to lock in manufacturing processes early due to the large hurdles of
documenting the bioequivalence of post-approval changes. The industry as a whole typically has
low capacity utilization (high margins often are used to justify this) and suboptimal yields.
However, the threat of generic competition (though this is still pending for biologics), cost
pressures, lobbyists, and globalization are forcing the industry to improve operations. Those
companies without internal capabilities, capacity, and expertise, often choose to outsource
manufacturing to contract manufacturing organizations (CMOs).
7 Murray, Fiona. Class Lecture: Building a Biomedical Business. MIT Sloan School. November 2003.
8 ibid
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2.4 BIOPHARMACEUTICAL OUTSOURCING
Biopharmaceutical companies are focusing on operational efficiency more than ever before due
to the cost pressures, complex pricing, regulations, and globalization. In order to improve
operational efficiency, many firms have chosen to outsource parts of the value chain. "Faced
with downward pressure on prices, generic substitution and weak pipelines, senior
pharmaceutical executives decide that they can no longer afford to be so vertically integrated,
and that they need to utilize more of their assets for in-licensing and alliances for new
products. 9" Jim Miller, president, PharmSource.
A market survey conducted by Arthur D. Little (ADL) and Solvias in 2002 suggests that the only
core activities in the pharmaceutical value chain are lead identification, lead optimization, and
marketing. Thus, the areas of the value chain that are considered non-core, and should
potentially be outsourced, according to the survey include: research, development, and
manufacturing. Figure 2-3 shows the pharmaceutical value chain again, with the non-core
activities that can be potentially outsourced shaded.
Deveopment
Re Search Discovef y Product launch
N2e phas r as Pas e Drug t \
Tx g, t " Lead identtfacation 7/nc i | i registratin Mallu Marketinidntfiaton and oplimizationFomlto factule Phase I
Targets L e ad .. NDA :
Figure 2-3: Outsourcing Value Chain with Milestones for Biologics and Pharmaceuticals (Shading Depicts
Non-core Activities)
Figure 2-4 depicts the operations that biotech and pharmaceutical companies outsourced based
on a survey conducted by PRTM in 2002". The finishing and packaging steps were the ones
most outsourced based on the survey. Since these steps are not necessarily specific to the
biopharmaceutical industry, and have the least potential for generating or being protected by
9 Challener, Cynthia. "Looking at the Next Phase in Pharmaceutical Outsourcing." Chemical Market Reporter.
April 14, 2003.
10 Parkhurst, Jennifer. "Maximizing Your Contract Manufacturing Relationships." Contract Pharma. June 2004.
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intellectual property, it is no surprise that they would have the highest percentage outsourced as
there are a plethora of contractors and the activities are non-core to the biopharmaceutical firm.
Socodry _ _ _ _ _ _ _ _
Acbt P rma iS_____________
Inednt (API)W g
Cte
04 14% 2W/ 30% 40% 0% 0% 77% 80 90%
Source: PRIM 2002 Pbarma Cora Men acturer Survey
Figure 2-4: Outsourcing in the Biopharmaceutical Industry
Smaller biotech companies typically do not have the necessary capital or infrastructure to
manufacture their own drugs and thus rely on contract manufacturing organizations (CMOs) or
partners for production. In this industry, where time to market is critical, many companies rely
on CMOs to expedite the drug development process, as site builds are not only costly, but also
lengthy as well, and as such can significantly delay time to market. Aside from outsourcing
manufacturing, many biopharmaceutical companies, both large and small, outsource their
clinical trials to clinical research organizations (CROs).
Biopharmaceutical companies are faced with the same questions as others in different industries
when deciding to outsource. A few reasons for outsourcing in the biopharmaceutical industry
include:
. time to market
. avoidance of capital expenditure
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. flexibility
. cost containment (for products facing generic competition in particular)"
Time to Market
Time to market is the major driver for strategic sourcing decisions. Being first to market with a
pharmaceutical drug is critical for capturing the market and hence the revenue streams. Any
delays in the drug development process are directly correlated to lost revenue; any reduction in
the time to market can result in significant savings of revenue and potential market share gains.
To better understand the potential cost savings of reducing time to market, consider the
following example. If one assumes that a drug generates $100 million in peak sales and has a
gross profit margin of 35%, then the biopharmaceutical firm will generate $35,000,000 in
earnings over one year. If the time to market is reduced by one month, than one can estimate
that the firm will see additional earnings of $2,916,667. Taking into account the probability of
success, whereby only approximately 10% of drugs in development reach the market, the
potential expected additional earnings are $291,667. Though this number may seem low at first,
the results can be significant for drugs with higher peak sales and higher profit margins. It is in
the firm's best interest to reduce the time to market to see greater potential earnings. Often
times, because contract manufacturers are specialized and already have the necessary equipment
and employees trained, the time to market can be reduced by outsourcing.
Avoidance of Capital Expenditure
A firm can avoid capital expenditures through outsourcing since facilities, equipment, and
personnel are not directly billed to the company. By outsourcing, the firm does not need to
report the capital expense of the facility and equipment on their balance sheet. On average, the
cost to build a traditional pharmaceutical plant is greater than $500 per square foot. Thus, when
a pharmaceutical company considers building a new site for manufacturing a drug, they will
often look to outsource so as to avoid the initial capital expense of building the facility and
purchasing equipment. Outside of the capital expense, there are the additional costs of training
" Booth, Robert. "Process-driven Outsourcing." Life Science Today. February 2002.
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existing personnel on new equipment, and or hiring new personnel to consider. Thus
outsourcing is sometimes viewed as the least expensive alternative in the short-term.
To better understand the reasons why a firm would elect to outsource to avoid the capital
expenditure, consider the following example. Suppose a firm has discovered a new oncology
drug that needs to be lyophilized in order to be delivered as a sterile injectable final drug product
to the patient. The firm would have to invest in excess of $10 million to acquire the necessary
equipment and expertise to do this finishing step. When faced with this large capital expense, a
firm may elect to outsource this finishing step to a contractor that specializes in fill finish and
could provide this service at a more attractive cost.
Flexibility
One reason that many firms elect to outsource is to obtain flexibility in production. A CMO can
provide the firm with a wide range of equipment and expertise that the firm could not otherwise
afford to keep in-house. When a firm needs to react quickly, either due to fluctuations in the
market, entering a new market, mergers, or acquisitions, outsourcing often provides the
flexibility that is needed. In addition, by using CMOs, a firm can gain access to new equipment
and technologies prior to making the purchase themselves for performing in-house.
Outsourcing to a CMO often involves signing a contract for 3-5 years, which many would argue
reduces the flexibility of the firm. However, since most CMOs understand the benefits of being
flexible, they are often willing to reevaluate contracts based on market demands. On the other
hand, CMOs often have very rigid schedules and are not able to offer clients much flexibility
because the time slots for production are filled by other clients.
Cost Containment
The stage in the life cycle (introduction, growth, maturity, and decline) that the drug product is in
provides another reason to outsource. Early in development, the probability of success and
confidence in market penetration is often low, and thus firms may elect to outsource to hedge.
Likewise, as the drug enters the maturity and decline stage and is met with generic competition
there is also the inclination to hedge costs. The margins and market share of drugs that are
facing generic competition are often reduced. One option that many firms elect to perform when
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a drug approaches patent expiration or already has generic competition is to outsource most of
the value chain for the drug. Essentially, by outsourcing, the firm is electing to not invest any
further funds, aside from the minimum required to produce to meet demand. However, the cost
of outsourcing can still be substantial since the company may need to train and support the
contractor.
2.4.1 Contract Manufacturing Organizations
In order to improve operational efficiency, many firms have chosen to outsource parts of the
value chain to contract service organizations (CSOs). The contract manufacturing industry for
pharmaceuticals was valued at $6 billion in 2002 by Arthur D. Little (ADL) 2 . The industry can
be segmented into active pharmaceutical ingredient manufacturing, which is valued at $2.5
billion; custom synthesis of intermediates, which is valued at approximately $3 billion; and
early-stage development manufacturing, which accounts for roughly $500 million (ADL,
2002).
2.4.2 Selection and Assessment of Contract Manufacturers
Contract manufacturers should be selected and assessed based on their performance against a set
of metrics surrounding regulatory compliance, assurance of supply, quality, service, cost, and
continuous improvement14 . The following balanced scorecard method of assessing CMOs was
suggested by Golden from GlaxoSmithKline 5 :
Regulatory Compliance: The CMO should be measured against its compliance with all
regulatory requirements. In order to select a CMO, the firm should review the supplier's
regulatory compliance history with regulatory agencies including the FDA, EMEA, OSHA,
EPA, etc. The firm should assess whether or not the supplier goes "beyond compliance,"
meaning it has the necessary measures in place to ensure both the spirit and letter of the law and
12 Challener, Cynthia. "Looking at the Next Phase in Pharmaceutical Outsourcing." Chemical Market Reporter.
April 14, 2003.
'" ibid
14 Golden, Frank. "Reviewing the Pros and Cons of In-house API Manufacturing Versus Contracting the Process
Out." American Pharmacuetical Outsourcing. March/April 2003.
" ibid
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goes above and beyond this by ensuring a safe and healthy work environment. Golden suggests
the following scoring for regulatory compliance:
. 1 - current warning letter
* 2 - warning letter in the last three years
. 3 - no warning letter within the last three years' 6
Assurance of Supply: The CMO should be measured against its ability to deliver on time and in
full. One critical factor for the firm to assess is the CMO's financial stability and ability to
assure supply. In addition, the firm should assess a supplier based on its past delivery tardiness,
whether they have delivered the full amount, and whether the proper documentation such as
MSDSs were included. Golden suggests the following scoring for assurance of supply:
. 1 - current severe supply issues (i.e. financial instability)
. 2 - past supply issues
. 3 - no supply issues' 7
Quality: The CMO should be measured on its ability to produce product per specification. The
firm should assess a supplier based on whether it meets cGMP standards, has current validations,
ongoing continuous improvement efforts, customer satisfaction, and number of quality assurance
and quality control staff. Golden suggests the following scoring for quality:
. 1 - significant quality issues
. 2 - manageable quality issues
. 3 - no quality issues' 8
Service: The CMO should be measured on its service to the firm with respect to its problem
management and resolution efforts. The firm should assess a supplier based on its lead-time,
ability to respond to fluctuations in demand, responsiveness to changes requested by the firm,
and ability to respond to changes in the product or process specified by the firm. In addition, the
16 Golden, Frank. "Reviewing the Pros and Cons of In-house API Manufacturing Versus Contracting the Process
Out." American Pharmacuetical Outsourcing. March/April 2003.
" ibid18ibid
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firm should assess the supplier relationship with regards to communication, administrative staff,
and accountability. Golden suggests the following scoring for quality:
. 1 - Not responsive
. 2 - Somewhat responsive
* 3 - Responsive19
Cost: The CMO should be measured on its ability to meet the total cost of ownership
requirements set by the firm. The firm should assess a supplier based on its competitiveness,
pricing, efficiency, yield, waste reduction, and disclosure of cost structure. Golden suggests the
fbllowing scoring for quality:
. 1 - Not well managed
. 2 - Managed per request
. 3 - Well managed2 0
Continuous improvement: The CMO should be measured on its continuous improvement
efforts. The firm should assess the supplier's willingness and degree of engagement in
continuous improvement efforts, process development, and sharing of improvement gains.
Golden suggests the following scoring for continuous improvement:
. 1 - Not cooperative
. 2 - Willing to participate
. 3 - Proactive2
Balanced Scorecard: The firm can select varying weights for the requirements based on the
needs of the project. The resulting ranking should be assessed objectively and compared with
competitors as well as to in-house capabilities in order to assess and select the best CMO for the
project.
'(iolden, Frank. "Reviewing the Pros and Cons of In-house API Manufacturing Versus Contracting the Process
Out." American Pharmacuetical Outsourcing. March/April 2003.
20 ibid
21 ibid
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2.5 COMPETITIVE ANALYSIS OF MANUFACTURING STRATEGIES
Figure 2-5 highlights the degree to which biopharmaceutical companies use contract
manufacturers for clinical and commercial production based on a survey conducted in 200022.
Virtual biopharmaceutical firms (those that outsource all manufacturing) are not included in
Figure 2-5.
% Small % Large
Biopharmaceutical Biopharmaceutical
% Overall Companies Companies
Produce Inhouse (No Outsourcing) 12 19 5
Outsource Pilot Plant to Phase II 35 47 24
Outsource Commercial Production 53 34 71
Figure 2-5: Biopharmaceutical Use of CMOs versus In-house Production for Clinical and Commercial
Product23
Based on interviews conducted by the researcher and outside research, the following
biopharmaceutical companies provided their respective viewpoints on outsourcing and vertical
integration:
Roche uses a standard protocol to evaluate CMOs based on products they have manufactured in
the past, capacity, technical capabilities, cost of goods, and past experiences. "Key attributes in a
custom manufacturer from a pharmaceutical company perspective include trust, adherence to
GMP guidelines, technical expertise, partnership skills, reliability and open communications."2 4
Albert Kuonen, head of global strategy and supply chain.
AstraZeneca evaluates CMOs on their technical aptitude, speed, and proven track record. "The
decision to select a custom manufacturer is made in a formalized outsourcing project proposal
that is approved by the project sponsor. Key elements of the proposal include technical
capabilities, speed, commercial terms, good track record from previous outsourcing projects, and
22 Fox, S. "Biopharmaceutical Contract Manufacturing: A Growing Demand for Capacity Spurs the Industry".
American Pharmaceutical Outsourcing, 1: 17-24 (2000).
23 ibid
24 Challener, Cynthia. "Looking at the Next Phase in Pharmaceutical Outsourcing." Chemical Market Reporter.
April 14, 2003.
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the supplier's willingness to work with continuous improvements." Gunnar Lager, director of
outsourcing and procurement for bulk drugs at AstraZeneca.
Biogen IDEC prides itself on its manufacturing capabilities for its biologic drugs. When
questioned as to its outsourcing strategy, it was noted that they would highly consider
outsourcing drugs in the small molecule arena as there is excess CMO capacity; however, they
plan on manufacturing biologics in-house.
Millenium is what many would consider a virtual biopharmaceutical firm since they do not have
internal manufacturing capabilities, although they do have internal development capabilities.
Millenium plans on continuing to rely on their relationships with CMOs to manufacture their
pipeline. They do not, however, rule out potentially acquiring or building manufacturing
capabilities in-house.
Genentech is the oldest biotech company and thus has significant internal manufacturing
capabilities. They use CMOs mainly because they are capacity constrained. Plans for adding
additional capacity are in process; however, Genentech does not foresee eliminating their
relationships with contract manufacturers.
2.6 GENZYME'S MANUFACTURING STRATEGY
Genzyme is considered to be a highly vertically integrated company. In their 2003 Annual
Report, they stated "We have built a vertically integrated organization, with the skills necessary
for every step from discovery through to commercialization and delivery of products to
physicians and patients." 26 This strategy is apparent throughout the organization and underlies
all strategic sourcing decisions. Figure 2-6 is a schematic of Genzyme's vertical integration
strategy.
25Challener, Cynthia. "Looking at the Next Phase in Pharmaceutical Outsourcing." Chemical Market Reporter.
April 14, 2003.
2 Genzyme Corporation 2003 Annual Report available from http://www.genzyme.com
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Figure 2-6: Genzyme's Corporate Strategy of Vertical Integration
When Genzyme began manufacturing of its biologic compounds, there was little alternative to
manufacturing in-house as very few CMOs possessed biologic drug manufacturing capabilities.
Genzyme chose to manufacture in-house in order to control their proprietary technology; they
grew and developed biologic manufacturing expertise as a core competency. When Genzyme
acquired GelTex, the polymer based product Renagel was added to their product portfolio and
received FDA approval in 1998. GelTex had arrangements with CMOs and thus Genzyme
continued to outsource its manufacturing. Genzyme's vertical integration strategy that had been
highly successful and lucrative on the biologic side of the business coupled with strategic reasons
led Genzyme to pursue manufacturing in-house and develop internal capabilities for
manufacturing of polymer and small molecule drugs. A site in Waterford, Ireland was built for
the production of final drug product and packaging of Renagel.
Genzyme has continued to grow its internal production capabilities of small molecule and
polymer based drugs. Figure 2-7 depicts Genzyme's capabilities and options for where to
perform in-house or outsource activities for early stage to commercial manufacturing of small
molecule and polymer based drugs. Waterford is the main site for development and commercial
manufacturing of drug product. GD3, a site dedicated to research and development, has a
planned expansion which will enable further in-house development. Haverhill, England has the
full range of capabilities for API development and manufacturing for small molecules and
polymers. San Antonio, the site of ILEX Oncology has laboratory facilities for development of
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high potency compounds. The researcher focused on the capabilities in Waterford, Haverhill,
San Antonio, and GD3.
API
Clinical Pilot Plant Commercial
Discovery Development Manufacturing Manufacturing Manufacturing
Scale Lab g - kg g - kg Kg kg - tons
Location Haverhill Haverhill Haverhill Haverhill Haverhill
Liestal Liestal Liestal Liestal Liestal
GD3 GD3 GD3 GD3
(2005 plan) (2005 plan) (2005 plan) (2005 plan)
San Antonio
(ILEX)
Outsource Outsource Outsource Outsource Outsource
DRUG PRODUCT
Clinical Pilot Plant Commercial
Discovery Development Manufacturing Manufacturing Manufacturing
Scale Lab g- kg g - kg Kg kg - tons
Location Waterford Waterford Waterford Waterford Waterford
GD3 GD3 GD3 GD3
(2005 plan) (2005 plan) (2005 plan) (2005 plan)
Outsource Outsource Outsource Outsource Outsource
Figure 2-7: Genzyme's Manufacturing Capabilities for Small Molecule and Polymer Based Drugs
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Chapter 3: Strategic Sourcing Decision Tools
3.1 CHAPTER OVERVIEW
This chapter is an overview of the make versus buy decision process and details the vertical
integration strategy as it relates to the Genzyme corporate structure. The major factors related to
the options for make versus are identified and discussed. Analytical tools, specifically the
sourcing framework methodology are introduced and explained as they relate to strategic
sourcing decisions at Genzyme.
3.2 VERTICAL INTEGRATION
Strategic sourcing, make versus buy, and insourcing versus outsourcing are all common names
for the same thing - the degree to which a company chooses to be vertically integrated. When a
company elects to manufacture commercial products utilizing precursor agents and conducts
associated services such as quality assurance, regulatory adherence, and marketing, internally it
is considered to be vertically integrated. Essentially, a vertically integrated company owns the
entire value chain. Figure 3-1 is a schematic of the varying degrees of vertical integration within
the biopharmaceutical industry, with a fully integrated pharmaceutical company, or FIPCO,
being completely vertically integrated.
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Figure 3-1: Categorization of Varying Degrees of Vertical Integration
An example of a highly vertically integrated company is the semiconductor manufacturer, Intel.
Many would argue that Intel's high degree of vertical integration is one reason the company has
maintained its level of success. In the 1990s, manufacturing capacity in the semiconductor
industry became tight, and many semiconductor firms that contracted out manufacturing were
unable to make their delivery commitments. Intel, however, which conducted its own research
and development, manufacturing, and marketing, was able to meet demand and thus thrived.
Genzyme, like Intel, has chosen a vertical integration strategy to not only ensure supply but also
for additional reasons such as gaining the learning benefits that come from manufacturing and
developing in-house.
3.2.1 Benefits of Vertical Integration
Although many firms have elected to outsource some or all of their manufacturing activities,
there are a number of benefits to vertical integration including:
. development and retention of core production capabilities
27 Hayes, Pisano, Upton, and Wheelwright. Operations, Strategy, and Technology- Pursuing the Competitive Edge.
Wiley & Sons. 2005.
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. learning, which can be applied to future products or programs
" direct control over costs
. control over quality assurance measures
. improved coordination
. reduction of dependency on suppliers
. protection of proprietary information
. control against risk of supplier failure
3.2.2 Drawbacks of Vertical Integration
While vertical integration has many benefits, they must be weighted against the cons of
performing functions in-house, namely:
. reduction in flexibility because firm is locked into the manufacturing of a given product
or technology
. capital expenditure of initial start-up or acquisition
. difficulty in integrating the various operations
. required additional training of employees and or hiring of new employees
. potential for cumbersome management and associated bureaucratic issues
. potential cost disadvantage if a strong set of suppliers exist
3.3 VERTICAL INTEGRATION DRIVERS
In order to better understand a company's vertical integration strategy, one needs to explore the
key drivers that may move a company to the vertical integration approach. In an article on when
to vertically integrate, John Stuckey and David White sited the following four reasons for
vertical integration:
1. The market is too risky and unreliable - it 'fails"
2. Companies in adjacent stages of the industry chain have more market power than
companies in your stage
3. Integration would create or exploit market power by raising barriers to entry or allowing
price discrimination across customer segments
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4. The market is young and the company must forward integrate to develop a market, or the
market is declining and independents are pulling out of adjacent stages28
The first reason, "market failure," is the most important reason to vertically integrate. Market
failure can occur when there is market uncertainty, either too few buyers and or sellers, frequent
transactions, or a high degree of specificity in the asset. If there are too few sellers, the result
can be monopolistic pricing; if there are too few buyers, they can extract market power. Figure
3-2, from Stuckey and White, depicts the potential market structures that result from varying
degrees of buyers and sellers.29 Vertical integration is suggested when a market fails to protect
the firm against monopolistic dealings.
0
0I--
E
One Few Many
Number of Buyers
Figure 3-2: Market Structure with Regards to Buyers and Sellers3
The second driver, "defending against market power," is another rationale for vertical
integration. This driver is a protective measure to ensure that the supplier cannot exert their
market power by charging exorbitant prices or reducing supply. Another reason why firms often
choose to vertically integrate when they see a neighboring member of the value chain with power
is that they see it as an attractive market and thus choose to enter by vertically integrating.
28 Stuckey, J. and White, D. "When and When Not to Vertically Integrate." SloanManagement Review, Vol. 34, No.
3, Spring 1993.
29 ibid
3 ibid
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The third driver, "creating and exploiting market power," is a strong strategic justification for
vertical integration. If a firm recognizes that through vertical integration the barriers to enter the
market are greater, it is in the firm's best interest to vertically integrate. However, it can often be
extremely expensive to do so.
The last driver, "responding to industry life cycles," is often a necessary reason to vertically
integrate. When an industry is still in its infancy, such as the biotech industry is, vertical
integration is necessary because there are limited outside capabilities for manufacturing and
associated activities. Likewise, when an industry is mature or declining, vertical integration may
also be appropriate to ensure supply across the value chain as outside or contractual players exit
the declining market arena.
3.4 FACTORS FOR IMPLEMENTATION OF VERTICAL INTEGRATION
There are four major factors a firm should consider when deciding to vertically integrate (as
outlined by Beckman and Rosenfield (2005)): alignment with firm's strategy (strategic factors),
the overall capacity available to the firm and in the industry (market factors), operational
requirements (operational factors), and economic factors. 3 ' A company should first assess its
core capabilities and then determine a strategy for defending these in the competitive
marketplace. Next, it should assess what non-core capabilities would be applicable for
outsourcing by evaluating strategic factors, market factors, operational factors, and economic
factors.
3.4.1 Strategic Factors
Aside from the tactical concerns such as reducing costs or increasing capacity, there are strategic
issues that need to be addressed prior to implementing vertical integration. It is vital to assess
the firm's overarching strategy prior to making a vertical integration decision. Alignment with
31 Beckman, S., and Rosenfield, D. Operations Leadership. To be published by Irwin McGraw-Hill.
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the firm's overall strategy is essential in order to maximize buy-in internally and externally from
shareholders. Questions a firm should ask with regards to the strategic factors include:
. If developed in-house, is the time-to-market less than if contracted out?
. Does having this capability in-house allow the firm to leverage off of their existing
knowledge?
. Will this technology give the firm an advantage with future product portfolios?
. Does bringing this capability in-house provide additional benefits beyond having simply
the technology in place?
. Does the firm have the necessary resources (i.e. personnel) to work on this without
impinging on current projects?
3.4.2 Market Factors
In order for a firm to determine what parts of the value chain to own, it needs to understand the
industry dynamics and market factors. As was discussed in Section 2.3 on drivers of vertical
integration, market failure is a prime reason to vertically integrate. The market power that a firm
can obtain or lose is an essential factor to consider in the vertical integration assessment. A firm
should assess the entire industry dynamics to determine how reliable it is and then decide
whether to vertically integrate. In order to understand the overall industry attractiveness, the
firm should perform a Porter's Five Forces analysis on the industry, assessing buyer power,
supplier power, competition, substitutes, and barriers to entry. This analysis will allow the firm
to assess what parts of the value chain they can integrate into and extract significant rents from.
Questions a firm should ask with regards to the market include:
. Is there an externally available source that serves this market?
. Can the firm leverage competition among contract manufacturers to reduce costs and
improve quality?
3.4.3 Operational Factors
In order for a firm to decide to vertically integrate, they should assess the relationship between
research, development, and manufacturing. The firm needs to assess its internal resources and
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constraints in order to determine whether vertical integration is feasible. Questions a firm should
ask with regards to its operations include:
. Is there space in the existing facilities for this equipment?
. Will the equipment be used for more than one product?
. What is the expected utilization rate of the equipment?
. Does this piece of equipment allow the firm to troubleshoot existing manufacturing?
. Does the firm have employees that have significant experience in this area?
3.4.4 Economic Factors
Aside from the strategic, operational, and market factors, a firm must also assess the tangible
economic factors of vertically integrating. The firm should calculate the net present value of
sourcing internally and compare it with outsourcing, taking into consideration the transaction
costs associated with contracting out. Questions a firm should ask with regards to the economics
of vertical integration include:
. Is the overall expense for sourcing internally (including capital costs for equipment and
space, personnel costs for hiring and training, and costs associated with regulatory
compliance) for the equipment less than the cost to source externally (including
transportation and logistics costs)?
. Are the transaction costs including searching, legal contracting, and coordinating with an
external source relatively low?
. Can the equipment be fully depreciated during its operational life?
. Are there tax benefits associated with sourcing internally or outsourcing?
3.5 STAGES OF THE VERTICAL INTEGRATION DECISION
The complex strategic question of vertically integrating is one that needs to be revisited often as
the market and firm dynamics change. In a chapter on vertical integration, Beckman and
Rosenfield32 cite five ways of making a vertical integration decision. These five steps are:
32 Beckman, S., and Rosenfield, D. Operations Leadership. To be published by Irwin McGraw-Hill.
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1. Assess company's core competencies
2. Evaluate the industry's value chain
3. Identify options
4. Assess and select option
5. Implement
In step 1, the purpose is to conduct a core/non-core capability analysis of the firm. Core
capabilities are ones that are determined to be best-in-class and create high value; they are
typically activities that the company can perform better than the competition and potential
entrants. Core capabilities should be unique, in that they are rare in the industry, not easy to be
copied by competitors, and there are not many substitutes for. Those capabilities that are
determined to be non-core are ones that should be considered to be outsourced, unless they are
strategically integrated with core activities.
Step 2 involves evaluating the value chain for the industry. As suggested by Stuckey and White
(1993)33, the firm should first perform a static analysis of the industry, searching for existing
cases of supply uncertainty and market power. This is accomplished by measuring economic
surplus throughout the value chain, identifying monopolies and oligopolies, and assessing
interdependence of stages throughout the chain. Then, a dynamic analysis of the industry should
be conducted in order to predict changes in market power along the industry value chain. A
Porter's Five Forces analysis of buyer power, supplier power, potential entrants, rivalry, and
barriers to entry should be conducted along each segment of the value chain. These analyses will
enable the firm to determine where it could capture more potential industry earnings (PIE) and
where there are threats to their existing value capture strategy.
After completing steps 1 and 2, the firm can then select those options for principal focus (step 3).
At this stage the firm assesses the vertical integration strategy, determining where to focus
resources on and what activities should be outsourced. It is important to separate the creation of
options, or the "brainstorming" step, from the assessment of the options (step 4). In step 4, each
3 Stuckey, J. and White, D. "When and When Not to Vertically Integrate." SloanManagement Review, Vol. 34, No.
3, Spring 1993.
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of the options should be assessed based on a typical cost-benefit analysis which would
encompass the elements of cost, quality, availability, and features, as suggested by Beckman and
Rosenfield (2005). Typical questions to ask when analyzing the cost-benefit of outsourcing
versus vertically integrating include:
Cost
. How much will investing in the insourcing option cost versus how much will outsourcing
save?
. Is the overall expense for sourcing internally (including capital costs for equipment and
space, personnel costs for hiring and training, and costs associated with regulatory
compliance) for the equipment less than the cost to source externally (including
transportation and logistics costs together with secondary contractual and legal costs)?
. What is the return on investment for owning or outsourcing options related to this
activity?
Quality
. What quality management systems need to be implemented if insourced, versus the
question of whether or not the contract manufacturers have the necessary quality
management systems in place in order to ensure quality?
. Are contract manufacturers willing and able to work with the firm to manage and
improve quality?
Availability
. If developed in-house, is the time to market less than if contracted out?
. Is there an excess of manufacturing capability in the market?
Features
. What new features (either product or service) will there be and can these be outsourced?
After assessing these factors and utilizing a cost-benefit analysis, a preferred sourcing option
may be selected by the firm. Then, the firm needs to implement the preferred option (step 5)
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either by establishing formal contractual relationships with the external manufacturers or
developing and or strengthening internal capabilities to perform the function in-house.
3.6 REASONS FOR OUTSOURCING
A firm may have an overarching vertical integration strategy, yet still elect to outsource portions
of the value chain. In a survey conducted by The Outsourcing Institute34 across multiple
industries, it was found that 55% of companies elect to outsource to improve the focus of the
company, 54% of companies use outsourcing to reduce or control operating costs, 38%
outsource to free up resources, 36% outsource in order to gain access to external world-class
capabilities, 18% outsource to reduce time to market, and 12% outsource to in order to mitigate
risk.
Like vertical integration, there are both pros and cons associated with the outsourcing alternative.
Figure 3-3 depicts a general listing of outsourcing pros and cons. This, or a similar list, should
be utilized by a company to determine what elements are most critical. In addition, a weighting
algorithm relative to these factors and the associated pros and cons should be developed and used
in order to decide if outsourcing is a viable strategic solution.
Outsource - Pros Outsource - Cons
Improved time to market Less control
More flexible Capacity crunches
Additional capacity and Monitoring remote sites
resources
Minimize risk Potential loss of proprietary
technology
Access to outside expertise Decreased internal
capabilities
Conserves capital Ensuring compliance
Figure 3-3: Benefits and Drawbacks of Outsourcing
3 The Outsourcing Institute surveys available from http://www.outsourcing.com/
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3.7 FRAMEWORKS FOR VERTICAL INTEGRATION AND SOURCING DECISIONS
Figure 3-4 is a framework developed by the researcher to assess the make versus buy decision
for product development capabilities. To use the framework tool, one ranks the criteria
according to how the user perceives the company prioritizes its strategic, market, financial, and
operational objectives (for example, a ranking of high means the company highly values this
criterion). Then, an options matrix is filled out by scoring the option in terms of being a positive
attribute (i.e. the option will be flexible and thus it is positive). The options matrix allows the
user to rank various options as a function of strategic, financial and operational objectives and
through a weighting process an algorithm selects the preferred approach of outsourcing or
performing in-house. The framework is an analytical tool that uses selected weighting factors to
aid in the selection process and it therefore should be customized for use as an additional tool in
the strategic sourcing decision process
Options Matrix: insource vs. Outsource Development
Project: Example
Criteria Ranking Weight Option A: I source Development Option B: Source Development Externally
Score Score
Importance (Pstie Weghe Numeric (Positive, Weighted Numeric
(High, Medium, Insource (ostve, Weighted External Source Weighted
Lo)Neutral, Score SoeNeutrai, Score Score
Negative) Negative)
5 Learning High Learning from process Positive High 9 Minimal learning and Negative Low I
retained by corporation control over proprietary
9 processC.
1 Flexibility Low Equipment is not flexible Negative Low I Highly flexible Positive Medium 4
Corporate Culture Medium Culture strives to vertically Positive High 9 Culture strives to Negative Low I
integrate ertically integrate
Q Capital Expense Medium Initial capital expense Negative Low I Charges based on volume Neutral Medium 4
and time
G Learning Curve High Knowledge from going up Neutral Medium 4 Genzyme receives no Negative Low Ileaming curve may reduce financial benefit from
future costs learning curve
Uncertain Pipeline Medium Pipeline uncertainty means Negative Low I ighty flexible Positive High 9
0 equipment must be flexible
Personnel Low Hiring of full-time for short Negative Low I Contract manufacturers Positive Medium 4
term project; ternp workers have personnel and
from manufacturing equipment in place
Training Medium Learning curve; expertise not Negative Low I Contract manufacturers Positive High 9
in this area responsible for training
Tme to Market High [Lead-time for equipment and Negative Low I Protentially quicker to Positive H igh 9
getting up to speed market
A: Insource Development Option B: Source Development Externally
Numerical Equivalent Total 28 42
Qualitative Rating Total Low High
Best Option: Option B: Source Development Extenaily
Figure 3-4: Strategic Sourcing Options Matrix for Genzyme's Development Capabilities
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3.8 STRATEGIC SOURCING DECISION TOOL
To combat the inherent problems of assigning rather arbitrary weighting numbers to the make
versus buy decision, as was attempted in Figure 3-4, another framework was developed for
Genzyme management to use. Figure 3-5 is a decision tree for determining whether to insource
or outsource drug product development capabilities. This decision tree allows the user to
proceed through a methodical thought process of deciding whether to make versus buy but does
not constrain the user to assigning specific values and weights to the answers to questions. To
complement the decision tree, a questionnaire was also developed. Figure 3-6 is an example of a
questionnaire that can be used to determine whether a development capability should be brought
in-house. The user answers each question and fills in the weighting of importance for the
particular project. It addresses key factors from a strategic, market and economic, and
operational perspective. Though similar in concept to Figure 3-4, the researcher found that it
was more user friendly and thus more likely to be adopted by managers at Genzyme.
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Drug Product Development:
Insourcing vs Outsourcing Decision Tree
Directions:
Begin at green start arrow, then
follow the tree by answrng yes
or no to the questions until you
reach an orange diamond.
If developed in house, is Do we need this
the tkne-to-market less No developneni knowledge -+
than if contracted out? in-house?
Yes
Is this one of our core
competencies?
Yes
Do we need this
development knowledge
in-house? Y n5
Yes
Do we foresee (in the Do we foresee (in the Do we currenty use t
next 3.5 years) using next year) using this
this dosage form for dosage form for ckkilcal
conical trials? tri16?
Yes
Do we have space in Do we need to meet
-Yes our existing facililes for No OWe standards? No -o.
this equipmert?
Yes
yes
Do we foresee (in the Do we foresee (in the Do urrN next 3-5 years) No next year) No manufacture in this
manufacturing in this manufacturing in this dosage form?
dosage form? dosage form?
Yet s
WVA we be able to use
Yes the equipment for scale- No
up purposes?
Yes: Loci le Wnmnar
Crn Wfg Site
is the captal expense
for the equipment Ies NO Equipmgtthan the cost to sourceA n
exerntay ?
Yes
Do we have employees Trakn*ng
that have signimat NO ----- hiring _*
experience In this area? Required
Yes
Figure 3-5: Drug Product Development Insourcing
CMOs Have Identified Capabilities and Capacity
versus Outsourcing Decision Tree for Products Where
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Development Questionnaire for Bringing in New Capabilities
Directions: Please answer the following questions by checking the appropriate yes/no box.
Criteria Ranking
Weight
High
High
High
High
High
High
High
High
High
High
High
High
High
Strategic Perspective Yes No
0 @
If developed in house, is the time-to-market less than if contracted out?
Does having this capability in place allow us to leverage our existing knowledge?
Does bringing this capability in house provide additional benefits beyond having simply 0
the technology in place (i.e. synergies from learning about the API)?
Will this technology give us an advantage with future product portfolios? 0
Market and Economic Perspective Yes No
® 0
Can we externally source this?
Do we have the necessary resources (i.e. personnel) to work on this without impinging 0 g
on current projects?
What is overall expense of sourcing internally (including capital costs for equipment
and space, personnel costs for hiring and training, and costs associated with NPV Inputs
regulatory compliance)?
What is overall expense of outsourcing (including transportation, logistics, legal, and NPV Inputs
coordination costs)?
Is the overall expense for sourcing internally (including capital costs for equipment and
space, personnel costs for hiring and training, and costs associated with regulatory 0
compliance) for the equipment less than the cost to source externally (including
transportation and logistics costs)?
Operational Perspective Yes No
® 0
Do we have employees that have significant experience in this area?
® 0
Does this piece of equipment allow us to troubleshoot existing manufacturing?
® 0
Do we have space in our existing facilities for this equipment?
® 0
Do we need the installation of the equipment to meet GMP standards?
® 0
Will the equipment be used for more than one product?
Utilization
What is the expected utilization of the equipment?ui m
Manufacturing Yes No
Is this equipment for API manufacturing or analysis?
Is this equipment for DP manufacturing or analysis?
Figure 3-6: Example of Development Questionnaire for Bringing in New Capabilities
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Chapter 4: Application of Strategic Sourcing Frameworks to
Encapsulation
4.1 CHAPTER OVERVIEW
This chapter describes a case study using the outsourcing frameworks that were developed by the
researcher. The chapter provides an evaluation of purchasing specific equipment to be able to
perform encapsulation in-house. In order to conduct this evaluation, a cradle to grave analysis of
the encapsulation process was performed by the researcher. In addition, a thorough assessment
of industry best practices, interviews with Genzyme personnel, equipment suppliers, and contract
manufacturers were integrated into the analysis and decision-making process in order to evaluate
the make versus buy decision.
4.2 CASE STUDY: ENCAPSULATION SOURCING DECISION
The largest product segment for pharmaceuticals is those that are orally administered, either in
liquid, tablet, or capsule form. Encapsulation, or the process of creating capsules for final drug
product, is often the method of choice for final drug product production for clinical studies.
During development through early stages of clinical trials, the manufacturing procedures and
specifications of the API and final drug product are not completely defined. Because of frequent
changes to the drug specifications, companies often prefer to use capsules as the drug product
because tablets require additional formulation work with excipients to ensure proper tableting.
In addition, capsules are typically preferred over tablets for clinical studies because they are
cheaper, formulations are easier and do not need to be thoroughly defined, and encapsulation
equipment is cheaper and easier to operate than tableting equipment.
An additional reason why companies prefer capsules to tablets in clinical studies involves the
regulations surrounding double blinding. To double blind for clinical trials, the drugs being
evaluated need to appear identical. Thus, if the active drug is in tablet form, it is often put into a
capsule in order to have a placebo appear identical to it. From a production and cost basis, it is
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usually preferred to place the active drug and placebo into capsules rather than producing as
tablets during research and development and early clinical trial phases.
Often, capsules are used in early clinical studies, typically through Phase II, because of the
aforementioned reasons. Once the drug enters Phase III, it is preferred to use the same dosage
form as would be used for commercial production, as shown in Figure 4-1. Marketing studies
report that patients prefer tablet dosage forms to capsules, and thus many firms elect to
reformulate into tablets for commercial production. Due to regulations, often the firm will make
the formulation changes and trial the drug as a tablet in Phase III. Thus, capsules are typically
only used for early stage clinical trials and drug development.
Full
R&D re- cale arketmngR&D cPnia Phase l Phase I Phase ) l &clinical Produc- Sales
tion
Y Y
Capsule CommercialForm
Figure 4-1: Preferred Drug Product Formulation in Different Stages of the Value Chain
In order to evaluate the need for encapsulation production to be performed by Genzyme in-
house, the following was evaluated:
. Pipeline requirements and marketing needs
. Equipment (including all auxiliary equipment) specifications
. Location for performing encapsulation in-house, specifically with respect to having as a
development capability or production capability
. Tax advantages
. Site expertise
4.3 ENCAPSULATION OVERVIEW
A process flow chart depicting the encapsulation process is shown in Figure 4-2. Material stored
in IBCs including API, filler, and lubricants is transferred to the mill, sieve, and blender,
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undergoing a similar front end process as that which is done for tableting. This powder blend is
then transferred to the automatic capsule filler, as are empty capsules. The filler automatically
rectifies the capsules, then separates, fills, rejoins, and ejects the filled capsules. These capsules
then move on to a deduster or polisher to remove residual powder. Samples are pulled off at this
stage for inspection. The capsules then are conveyed to a check weigher, where empties and off-
specs are rejected. The finished capsules are sent off for packaging.
When producing drug product for clinical trials, it is preferable to have as few batches produced
per trial to reduce the lot to lot variability as a confounding factor in the trial. Due to regulations
on the study design and blinding conditions, a firm typically only runs one packaging run for all
of the drug product. Thus, many firms elect to produce large batch sizes of clinical trial material.
The largest batch size may be limited by the mill sieve and blend equipment in the early stage of
processing as shown in Figure 4-2.
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Capsules Blend
Blend
FigureFiller (Auati
rectification, separation, Dedust/ wChec reby km Packagingfilling, joining and Polish Weigher in d
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Figure 4-2: Encapsulation Process Flow Chart
4.3.1 Equipment Overview
Encapsulation is the finishing step of the drug product process whereby the formulation is put
into a capsule. There are two major types of encapsulators, the tamping, or dosing disc
encapsulator, and the dosator encapsulator. The advantage of the tamping style is that it is more
efficient for low bulk density powders, whereas the dosator has been reported to have difficulty
in creating the slug out of low bulk density powders. The disadvantage of the tamping
technology is that residual powder may build up and cause the capsule feeders to jam. The
dosator technology's drawback is that in order to create the slug, higher lubricant levels may be
required. Figure 4-3 highlights the system of action, advantages, and disadvantages of these two
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styles of encapsulation equipment. Figure 4-4 compares the mechanism of action, footprints,
costs, capabilities, speed, and delivery timeline for types of encapsulators that were evaluated for
purchase by Genzyme.
Tamping (Dosing Disc) Dosator
System of -Stations tamp powder -Stations compress slug
Action .Tamped powder emptied of powder
into capsule body "Slug vacuum transferred
into capsule body
Advantages More efficient for low bulk Cleaner - may not need
density powders polisher
Disadvantages -Residual powder "Formulation may require
collection may jam higher lubricant levels
capsule feeders
Figure 4-3: Comparison of Types of Encapsulators
Footprint mm) excluding IBC Potential Capability with change parts) Capsules Per Hour
Machine Mechanism L W H Cost w/anc powder pellets tablets liquids Min Max
K9Oi retrofit to Kl5Oi (CE) tamping/auto 1210 1300 2310 $135,000.00 Yes Yes Yes 90,000
K40i tamping/auto 1283 940 2134 $166,005.00 Yes Yes Yes Yes 40,000
CD-40 (CE) dosator/auto 1425 985 1760 $114,263.00 Yes Yes Yes Yes 40,000
MG2 Futura (CE) dosator/auto 2090 2040 1995 $299,215.00 Yes Yes Yes Yes 6,000 48,000
MG2 Suprema (CE) dosator/auto 1980 1790 1995 $149,100.00 Yes Yes 48,000
SegonQ SF-40 CE) tamping/auto 800 985 1700 $ 85,000.00 Yes Yes 5,000 40,000
STI In-cap tamping w/benchtop/auto 650 620 1645 $ 49,200.00 Yes Yes Yes Yes 3,000
IMA Zanasi 6F dosator/auto 920 1150 1880 $114,003.00 Yes Yes Yes Yes 6,000
1MA Zanasi 8F dosator/auto 920 1130 2039 $166,706.00 Yes Yes Yes Yes 8,000
Figure 4-4: Comparison of Encapsulators
MILL, SIEVE AND BLENDER
The process flow for the making of powder for the capsules follows the same methodology as
that for tablets up until the tablet press. Material is granulated via the mill, sieve and blender
similar to the granulation process for tablets. The powder blend then is manually transferred to
the location of the capsule filler. If one assumes that the mill/sieve and blender can produce
batch sizes of 100 kg and fill weight of the capsules is 400 mg, the maximum number of capsules
that can be produced from the batch size of 100 kg (assuming 94% yield) is 235,000 capsules.
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CAPSULE FILLER
Empty capsules and the powder blend are fed into the capsule filler which automatically
rectifies, separates, fills, rejoins, and ejects the capsules. Filling is accomplished either via a
tamp style mechanism or a dosator. The tamp style is more common in lab scale equipment.
The dosator type is cleaner in that a compressed slug of powder is inserted into the capsule and
thus a polisher may not be required.
The capsules then flow down a deduster/polisher to remove any residual powder. Samples can
be taken either manually at set intervals or an automatic sampler can be installed to inspect
sample capsules at set times. The finished capsules are transferred to a check weigher where
empties and off-specs are rejected and scrapped. Rejects and wastes are incinerated. The
capsules may need to be 100% check weighed for quality control. The finished capsules then are
packaged in plastic lined drums to move to the packaging step.
PACKAGING
It is often more economical to hand pack small quantities (less than 1000 bottles). Semi-
automatic packaging equipment is recommended for quantities in excess of 1000 bottles. Figure
4-5 depicts the steps in the packaging process and recommends if it should be done manually or
with automated equipment.
Packaging Step Manual or Automatic
Labeling of primary container Semi-Automatic
Packaging of primary container and Manual
instructions into secondary container
Labeling of lot information on secondary Semi-Automatic
container
Securing secondary container with tamper Semi-Automatic or Manual
evident seal
Consolidating secondary containers into cases Manual
for shipping
Figure 4-5: Packaging Steps and Equipment Automation
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MATERIAL TRANSFERS
For small batch sizes, flexibility can be increased by transferring material by hand from one unit
operation to the next rather than having automatic conveyance of the capsules through the line.
Additional flexibility can be achieved by placing the equipment on castors to make them mobile;
therefore the equipment can be stored in alternative locations when not in use so as not to take up
critical clean room space.
4.4 MAKE VERSUS Buy APPLICATION
In order to assess the make versus buy decision, the frameworks developed for sourcing
decisions (Figure 3-5 and Figure 3-6) were used. Personnel at each site under consideration for
adding the encapsulation equipment were interviewed and asked to apply the frameworks. The
researcher evaluated the responses along with the additional secondary factors of tax advantages
and strategic plans.
It was identified that encapsulation is not one of Genzyme's core competencies and thus is a
candidate for outsourcing. If Genzyme elected to outsource encapsulation, time to market would
be quicker since the contract manufacturers have the expertise and necessary equipment already
in place. However, if Genzyme chose to perform encapsulation in-house, it is likely that over the
long term they may move up the learning curve and thus be at least competitive to CMOs with
regards to time to market. From a strategic perspective, Genzyme desires to be fully integrated,
and thus adding additional development capabilities is aligned with their mission. The
researcher evaluated all factors and options and determined the following:
. If Genzyme's focus is on clinical manufacturing capabilities for future products, then
locating encapsulation in a production facility is the best option.
" If Genzyme's focus is on performing Phase I and II encapsulation in-house, then
locating in a development facility is the best option.
* If Genzyme's focus is on time to market for current pipeline products, then
outsourcing is the best option.
- 55 -
In general, if Genzyme's major focus is on reducing time to market, then they should consider
outsourcing the initial production to a CMO that has the expertise and equipment already in
place. Simultaneously, they can build internal capabilities, be it acquiring and validating new
equipment, training or hiring new personnel, or building an entire new site. Once Genzyme has
their own internal capabilities, they can continue a relationship with the CMO (since they are
already qualified) as a second source.
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Chapter 5: Application of Strategic Sourcing Frameworks to High
Potency Compound Manufacturing
5.1 CHAPTER OVERVIEW
When Genzyme acquired ILEX Oncology, they successfully added new products to their
oncology pipeline. With the acquisition came new manufacturing demands and specifically one
in which Genzyme did not have expertise, namely high potency manufacturing. After a thorough
gap analysis, high potency manufacturing was identified as a manufacturing and development
gap, but Genzyme still needed to assess if they wanted to fill this gap by manufacturing in-house
or outsourcing manufacturing as ILEX had done. Before this assessment could be made,
(ienzyme needed to thoroughly understand high potency compounds and their manufacturing
requirements. The researcher conducted an evaluation of high potency compounds, toxicity
concerns and regulations, industry best practices, contract manufacturing capabilities, and
recommendations on strategic sourcing. This chapter discusses the analyses and
recommendations surrounding high potency biopharmaceutical manufacturing as it relates to
Genzyme Corporation.
5.2 HIGH POTENCY COMPOUNDS
The most generic definition for a potent drug compound is an active pharmaceutical ingredient or
intermediate that is capable of exerting strong chemical or physiological effects. More
specifically, high potency compounds are typically defined according to the standards below:
"A pharmacologically active ingredient or intermediate with biological activity at
approximately 15 micrograms per kilogram of body weight or below in humans
(therapeutic dose at or below 1 milligram).35" SafeBridge Consultants.
3 Additional information on high potency compounds and SafeBridge Consultants and is available from
http://www.safebridge.com/
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. API or intermediate with an occupational exposure limit (OEL) at or below 10 pig/M 3 of
air over an 8-hour time weighted average (TWA).
Aside from cytotoxic compounds, there are other classes of drugs that are considered highly
potent and need to be handled accordingly. Drug classes that make up the high potency market
include: cytotoxics, biomolecules, steroid hormones, peptide hormones, prostaglandins,
retinoids, and others. The cytotoxic market size alone was estimated to be $8 billion in 2000
(Datamonitor Consultants) and has seen significant growth. It is estimated that at least 10% of
drugs in development are high potency; this is up from approximately 5% in the 1990s.
5.3 MANUFACTURING CONCERNS
High potency compounds pose risks associated with carcinogenicity, mutagenicity, and
reproductive toxicity. There are regulations surrounding how manufacturers can produce high
potency compounds as detailed in Figure 5-1.
Can Cannot
Manufacture cytotoxics and non- Have same air supply for cytotoxic
cytotoxics in the same building compounds as non-cytotoxic
compounds
Manufacture multiple cytotoxic drugs Manufacture cytotoxics and non-
using same equipment, provided fully cytotoxics using the same
validated cleaning, accounting for equipment
levels of toxicity present
Have employees work with Rely solely on PPE
cytotoxics and non-cytotoxics, (PPE should be secondary
provided properly trained, monitored protection)
for exposure, and cleaning stations
are in place to assure no transfer of
material
Figure 5-1: Manufacturing Regulations for High Potency Compounds
High potency compounds are most hazardous in solid form, when there is a dust potential and
risk of particulate inhalation and or dermal contact. Therefore, any drying phases and final drug
product production phases are the most hazardous from an operator standpoint. The liquid phase
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of drugs poses much less of a concern, provided that the drug has a low volatility. The final drug
product, is the least hazardous, as it is diluted in liquid form or coated in solid form to prevent
unintended exposure.
High potency products pose exposure concerns via inhalation, dermal and ocular absorption,
accidental injection, and mechanical transfer to clothing, hair, pens, etc. As is the nature with
high potency compounds, dust matters; compounds with higher dust potentials pose a greater
concern. A product that is composed of fine light powders with potential for dust clouds is
deemed to have a high dust potential, a granular/crystalline compound that produces visible dust
that settles quickly is termed a medium dust potential compound, and those compounds which
are in pellet form or are non-friable solids are low dust potential compounds.
5.4 LEVELS OF TOXICITY
There are different levels of potency and toxicity for drugs categorized as high potency. There is
a correlation between the potency, toxicity, and the Occupational Exposure Limits (OEL); the
higher the potency of the compound (meaning that lower dosages are needed to be efficacious),
the higher the level of toxicity, and the lower the Occupational Exposure Limits (OEL). Figure
5-2 details the levels of toxicity, associated potency, OELs and necessary containment measures.
Category numbers are assigned to classes of high potency drugs based on the OELs. If a
company does not know the OEL, as was the case with Genzyme, than a conservative category
level is selected to ensure operator safety; typically a category 3 or category 4 level is assigned to
the drug while OELs are being measured.
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Toxicity Category Potency OEL Range (8 Necessary Containment
(Therapeutic hour TWA) *
Dosage)
1 Low >1000 pg/M3  eConventional open
> 100 mg/day equipment
eLocal exhaust ventilation
2 Moderate 100 to 1000 Ig/M 3  eLaminar flow/directionalized
10 - 100 mg/day laminar flow
.Engineered local exhaust
ventilation
eSemi-closed to enclosed
material transfers
3 High 10 to 100 pg/m 3  *Direct coupling and
0.01 - 10 mg/day enclosed system transfers
(e.g. split butterfly valves)
*Containment for every
disconnect
eUnidirectionalized air flow
booths
4 High 1 to 10 pg/m 3  eEnclosed processes
0.01 - 10 mg/day eDirect coupling transfers
eBariers/isolators
5 Extreme < 1 jig/M3  elsolators
< 0.01 mg/day *Automation/Robotics
INo human contact
Figure 5-2: Levels of Potency and Toxicity
5.4.1 Containment and Isolation
The terms containment and isolation with regard to high potency compounds are often used
interchangeably, yet there is a distinction between the two. Containment is used to protect
people and the environment at a validated control level, whereas isolation is designed to protect
the product from contamination by particulates, chemicals, micro-organisms, etc. The FDA is
concerned with the isolation mechanisms that are put in place, whereas OSHA regulates the
containment measures. In fact, these two regulations can often contradict each other. For
example, in order to fully isolate a potent compound, the FDA recommends positive pressure to
prevent contamination of compounds, whereas OSHA recommends negative pressure to prevent
escape of toxic substances. This can be accomplished by numerous methods, including a glove
box designed to isolate within a glove box designed to contain.
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Containment and isolation are necessary to protect people, product, place, and profit.
Containment and isolation protect people from hazards, product from cross contamination, place
(or environment), and profit (since these are high potency products, one mg of product is very
valuable). The researcher coined this the 4 P's of Protection: People, Product, Place, and Profit.
There are varying degrees of containment, as shown in Figure 5-3.
Cl)
0
C
C
Automation/Robotics
Isolators/Closed Transfers
Directionalized Laminar Flow
Laminar Flow
Local Exhaust
General Exhaust
Open Operations
4
4-00
C)
Figure 5-3: Levels of Containment for High Potency Compounds
5.4.2 Measuring Protection
In order to ensure protection for the people, product, place, and profit, the following
measurements should be taken:
People - measure OEL's (Operator Exposure Limit) and OEB's (Occupational Exposure Band)
Product - measure quality of the product
Place - measure OEL's and waste streams
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Profit - measure rejects and profits and loss
In order to establish and measure OEL's, the following limits need to be set and measured:
TWA (Time Weighted Average) - typically sample is drawn from the breathing zone of the
worker over an 8 hour period
I(Cit)
TWA =
Xt,
where ti is the period of time during which one sample is taken and Ci is the average
concentration over time period ti.
STEL (Short Term Exposure Limit) - 15 minute TWA concentration that may not be
exceeded even if the 8 hour TWA is within the standards. STEL should not exceed 3 times the
TWA limit.
5.4.3 Developing a Containment Strategy
Figure 5-4 is a flow chart for developing a containment strategy. The first step in developing a
containment strategy is to determine if an OEL is set. Then one needs to determine if the
chemicals have R phases, which is a European method for classifying various hazards. The next
step is to assign the compound a category based on the OEL. Next, one needs to determine the
dust potential and volatility. Once that is complete, the company should determine the exposure
pathway(s), duration of exposure, contaminant concentrations, and the overall exposure risk
potential associated with the manufacture of the material. Once an overall risk assessment is
performed, the company can identify mitigation approaches including isolation and containment
and conduct an overall cost-benefit study to determine which equipment should be selected to
reduce risks to acceptable levels.
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Toxicity
testing for
OEL and
hazards
No
Do the
chemicals
have R
hases
No
Yes No
Assign a
category/ is there infoIs there an Ye
OEL set? . hazard group on dustiness Yesbased on OEL and volatility?
or R-phase
Identify Level Select
fy L Appropriate
Containmentontainment Equlpement
Figure 5-4: Flow Chart for Developing a Containment Strategy
5.5 HIGH POTENCY MARKET ASSESSMENT
The market for high potency pharmaceuticals is a niche one, yet it is a highly lucrative niche
with high margins. There are significant barriers to entry for manufacturing, and thus many
small firms choose to outsource all manufacturing and act as a virtual company. However, some
companies have opted to build facilities dedicated to high potency compounds. An example of
one such firm is Abbott which initially contracted out their API manufacturing. They then chose
to invest in retrofitting a site in Ireland to manufacture high potency drug product. Now,
Abbott's strategy is to become a contract manufacturer for high potency drug product since their
facility is underutilized.
Another firm that has a strong pipeline of high potency products is Bristol-Myers Squibb (BMS).
BMS has internal manufacturing capabilities and they have assisted the International Society for
Pharmaceutical Engineering (ISPE) in creating exposure guidelines for high potency products.
Pfizer, another company with extensive high potency drug pipelines also has internal
manufacturing capabilities. Johnson & Johnson, an expert in containment for hormone drugs,
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Determine dust potential
- High (fine light powders
with potential for dust
clouds)
" Medium (granular/
crystalline compound,
visible dust that settles
quickly)
- Low (pellets or non-
friable solids)
Determine volatility
Determine
- Operator/Material Interface
- Task Duration
" Short (operation < 30 mins)
- Long (operation > 30 mins)
- Quantify the batch size
" Small Scale (gm - kg)
" Medium Scale (10 - 100kg)
* Large Scale (> 100kg)
- Exposure Potential
has years of experience with containment of these drugs; they are in the process of offshoring
production to lower labor-cost regions.
5.6 INDUSTRY ANALYSIS FROM A HIGH POTENCY CMO PERSPECTIVE
A Porter's Five Forces analysis on the high potency industry was conducted, assessing supplier
power, buyer power, substitutes, threat of new entrants, and rivalry.
Supplier Power: For a CMO in the high potency manufacturing industry, there are two sets of
suppliers, equipment suppliers and raw material suppliers. Equipment suppliers hold a large
amount of power in this regulated industry, given the high barriers to entry due to regulations
and certifications. In addition, there is a large learning curve for building expertise in equipment
manufacturing for high potency compounds. There are relatively few suppliers of equipment to
the high potency industry and they are able to extract high fees because of this. Raw material
suppliers are often commodity suppliers and typically the agreement with the pharmaceutical
manufacturer is tied to the price of raw materials. Suppliers in this industry have low to
moderate levels of industry power. Because of the high barriers to entry, there is little threat of
forward integration by suppliers. However, because of the regulated environment, there are
switching costs for qualifying a new supplier.
Buyer Power: Pharmaceutical and biotech companies are the buyers in this industry, and they
do not hold much power. There are only a few CMOs specializing in high potency drug
manufacturing, and they are able to charge oligopolistic prices. In addition, once a CMO is
qualified, there are significant switching costs associated with changing CMOs and thus the
buyer is likely to remain with the current CMO regardless of cost increases.
Substitutes: The threat of substitutes is low to moderate due to government regulations that
raise the switching costs for drug manufacturers to change CMOs. However, the threat of
substitutes increases when one considers that a buyer may choose to vertically integrate, and thus
performing in-house is a substitute for the CMO.
- 64 -
Threat of New Entrants: The threat of new entrants is moderate, even though there are
extremely high barriers to enter, both due to high capital investments and government
regulations. A firm wishing to enter the CMO market for high potency manufacturing requires
large capital investments, clinical and regulatory expertise, and relationships with
biopharmaceutical firms. However, as the industry appears more lucrative, there is a high
likelihood that potential entrants will be attracted to the market. A significant threat to existing
CMOs is biopharmaceutical firms that can backwards integrate into this market.
Rivalry: Competition in the CMO industry is strong overall, yet there is less rivalry in the niche
high potency CMO arena. CMOs choose to differentiate themselves by investing in consulting
certifications; however, this is not a sustainable advantage as it can be replicated.
The Porter's Five Forces analysis of the high potency CMO market illustrates a lucrative and
positive industry for the CMO. From Genzyme's perspective, as a buyer, they need to be aware
of the high power of the CMO and attempt to increase rivalry amongst the CMOs. In addition,
(enzyme can threaten to enter the market by vertically integrating in an effort to reduce CMOs
prices and increase quality and service.
5.7 CONTRACT MANUFACTURING ASSESSMENT
In addition to assessing contract manufacturers based on their performance against a set of
metrics surrounding regulatory, assurance of supply, quality, service, cost, and continuous
improvement36 as was discussed in Chapter 3, CMOs that specialized in high potency
compounds were also evaluated on the following criteria recommended by Zeitz et a13:
* Isolator technology for bulk manufacturing and packaging
* Remote control systems to allow operators to work outside of the critical area
" Automated self-adjusting equipment that minimizes potential operator exposure to the
active drug
36 Golden, Frank. "Reviewing the Pros and Cons of In-house API Manufacturing Versus Contracting the Process
Out." American Pharmacuetical Outsourcing. March/April 2003.3-7Zeitz, H., Tsch-pe, M., and Fernandez, C. "Outsourcing High Containment Operations." Contract Pharma. Dec
2004.
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. Process analytical technology (PAT) to reduce the level of manual or automated sampling
for in-process control and to continually monitor critical steps of the manufacturing
processes to make these processes more reliable
. Specially designed CIP (clean in place) or WIP (wash in place) equipment
. Separate production areas to contain any contaminants within the critical area. This
includes individual material and personnel locks that are controlled by HVAC systems
designed to provide increasing negative pressure towards the critical area
. Separate air-handling systems with high-efficiency particulate air (HEPA) filters in inlets
and outlets
. Secondary filters in outlets to prevent contamination of the HVAC system and ductwork,
and to act as a safeguard against environmental release of the active drug should the
primary outlet HEPA filter leak
* Docking systems in the production process to allow for transfer of API blends
. Closed manufacturing systems with a capability of handling substances with an
occupational exposure level (OEL) of 0.1 pg/m3 or less
. Walls, ceilings, and floors should be designed to resist repeated wash-downs and
aggressive cleaning to prevent dust deposits in cracks or corners
. Analytical testing labs furnished with appropriate containment equipment that is
separated from the normal lab area
Interviews with CMOs that specialize in high potency manufacturing were conducted in order to
determine the following:
. Size of facility
. Location
. Manufacturing capabilities
. Total number of employees
. Number of office employees
. Number of scientists
. Number of manufacturing employees
. Number of quality control and quality assurance employees
. Containment methods
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" Risk/insurance in case of exposure
* Drugs they currently manufacture
* Number of projects they currently have
" Lead times
* How they currently work with customers
* How many improvement teams meet on a regular basis
" How continuous improvement is measured
* Who drives/leads improvement activities
" Sample contracts
In addition, certification by SafeBridge Consultants, a consulting firm that specializes in
certifying high potency sites was noted. SafeBridge Consultants have currently certified, and in
some cases consulted in the building of, three CMO's sites: Organichem, Ferro, and Tetrionics.
These sites are considered by those in the industry to be the best of class. Based on the
interviews and research, a capability comparison chart of CMOs that specialize in high potency
manufacturing was developed. Figure 5-5 highlights the capabilities of selected high potency
CMOs and the scale of their operations. Other CMOs with high potency capabilities include Ash
Stevens, AAI, Cardinal Health, Sicor, Dellmar, Catalytica (formerly DSM), and Helsinn.
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High otency
Contract Manufacturer Capabilities Scale Certification
Kilo-scale lab, large isolator,
vacuum tray drier, two
hoods, reaction vessels on
Organichem Category 3-5 the 1000-L scale. SafeBridge
Ferro Pfanstiehl Laboratories Category 3-4 1 kg to 50 kg SafeBridge
2 R&D Suites , 5 GMP Kilo
Sigma-Aldrich (acquisition of Manufacturing Suites, Pilot
Tetrionics) Category 3-4 Plant SafeBridge
US DEA license to
Boehringer Ingelheim HPAI facility, labs, kilo lab, manufacture Schedule I
Chemicals Inc. (BICI) Category 3-5 pilot plan controlled substances
Solutia Pharmaceutical
Services Division Category 3-5 250 L - 630 L No
cGMP certificate by
Swedish Medical Products
Agency. FDA approval for
DuPont Chemoswed Category 3-4 5 to 15 kilo dry API supply to the USA.
No (30 year relationship with
Ben Venue Category 3-4 National Cancer Institute)
No (note- lost lawsuit to
Senetek for
ChemSyn Laboratories Category 3-4 30 - 100 gallon reactors nonperformance)
Lab facility and 2 mfg
facilities compliant with high
Aerojet Fine Chemicals (AFC) Category 3-4 containment guidelines No
Figure 5-5: Contract Manufacturers with High Potency Capabilities
5.8 MAKE VERSUS BuY ANALYSIS
The infrastructure that is necessary to handle high potency pharmaceutical compounds is often
the major driver for outsourcing to a CMO capable of high potency manufacturing. The capital
expense of building a high potency facility when the probability of success of the pipeline is still
relatively low is often daunting and thus outsourcing becomes a favorable alternative.
The researcher evaluated the key considerations that Genzyme should make before deciding to
perform high potency manufacturing in-house. First, a thorough assessment of Genzyme's
pipeline, not just in terms of number of products, but also in terms of volume, demand, and
number of reaction steps in the synthesis was conducted. The researcher evaluated reactor
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capacity, as well as the capabilities of outsourcing manufacturers. Of utmost concern to the
researcher and Genzyme in evaluating this particular make versus buy decision was the
additional hazards that the high potency products could bring to employees and cross
contamination risks if the products are manufactured, stored, or distributed along with other non-
high potency products.
Based on Genzyme's current pipeline of high potency compounds, it was determined that if a
facility were built, the financial burden would have to be carried by a single product until the
successful launch of an additional high potency product which could be five years away. In
addition, the volume of drug needed to be produced is on the order of kilograms per year, and
thus the idea of dedicating staff and a facility to such low volume production needed to be
carefully considered. However, even though high potency compounds have extremely low
volumes, they have high margins; therefore, the facility can remain underutilized yet still be
profitable.
Given all of the aforementioned factors, and by evaluating Genzyme's core competencies and
applying the sourcing strategy frameworks, it was determined that Genzyme should continue its
outsourcing arrangements with the CMOs that ILEX had established contracts with for high
potency drug manufacturing while it further evaluates the risks and benefits of performing high
potency manufacturing in-house. Genzyme can elect to build internal capabilities for high
potency manufacturing while they continue their relationship with the CMO for immediate
production of drugs ready for market. This ensures that there is no delay in time to market, as
this is the most important criteria for the sourcing decision. Should Genzyme elect to build
internal capabilities and develop manufacturing of high potency drugs as a core competency then
they should continue to foster the relationship with the CMO as a second source.
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Chapter 6: Conclusions, Recommendations and Future Activities
6.1 CONCLUSIONS
Compared to other industries, such as the automotive and computer industry, the
biopharmaceutical industry has been slower to implement the outsourcing of its manufacturing
activities. Consolidation in the biopharmaceutical industry is one of the major reasons why firms
have opted not to outsource. After a merger of firms, the new integrated firm typically has
excess manufacturing capacity and thus outsourcing is not a viable option at least in the near
term. In addition, post-merger, the economics of the market with respect to competitors may
continue to favor the in-house manufacturing option.
The major reason why larger biopharmaceutical firms perform manufacturing in-house is to
maximize their return on investment on their facilities and equipment by operating at near or at
full capacity. However, because of the low probabilities of success of drug development, it is
quite difficult to orchestrate the sizing of a manufacturing facility to achieve maximum capacity
utilization while avoiding or minimizing non-productive, idle capacity. In order to minimize
risks, some firms elect to use CMOs to manufacture in order to hedge potential monetary risks
against changes in demand without needing to have a facility remain idle.
After performing the six-month internship at Genzyme Corporation and conducting related
independent research and analytical studies, the researcher believes that the principal reason for
most biopharmaceutical firms to opt for outsourcing manufacturing is the reduction in time to
market for the product. This criteria "time to market" looms as the driving force in this decision
since it can result in high income streams earlier, especially for a "blockbuster" product. The
industry dynamics of the biopharmaceutical arena are quickly changing; as patents approach
expiration and generics and alternative therapies enter the market, biopharmaceutical firms need
to capture as much value as possible during the life-cycle of their patents. In order to capture the
most value, firms need to bring their drugs to market as soon as they are approved and have
adequate supply to meet demand. As was the case in the high potency drug manufacturing study
performed by the researcher, often outsourcing can reduce the time to market because CMOs
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already have in place the existing facilities, equipment, and expertise needed to manufacture
quality product in a timely fashion.
6.2 RECOMMENDATIONS
This thesis developed a framework for determining what technologies and capabilities Genzyme
should bring in-house for both API (active pharmaceutical ingredient) and DP (finished drug
product) for small molecule and polymer based drugs. Like all tools, this framework is only
helpful if used and applied correctly by management. The frameworks that were developed are
adaptable and easy to use, should Genzyme wish to adopt the framework for future make versus
buy decisions.
Based on the researcher's internship at Genzyme and associated research, the following
conclusions were drawn by the researcher regarding vertical integration and strategic sourcing in
the biopharmaceutical industry.
If a firm does not have secondary manufacturing sites to ensure supply of drugs in the case
of an accident or disaster, then the firm should qualify a CMO as an alternate source of
supply. Building additional facilities as back-up in the case of an accident or disaster is
extremely costly, especially in the biopharmaceutical arena. However, more costly is stocking
out of drugs due to an accident or disaster. Thus, a firm should conduct a full risk assessment
evaluation and then determine the potential loss of revenue should a site no longer be
operational. This risk assessment, including the cost-benefit analysis, can be used to determine
whether to construct additional capacity, i.e. a site build to provide "back-up" production
capability. In the researcher's opinion, the more preferable option is to qualify and develop an
ongoing relationship with a CMO as an alternate source of product rather than make the front-
end capital investment in facilities and equipment.
CMOs can provide valuable insight into manufacturing of compounds that a company has
little or no experience with. The case study involving manufacturing high potency compounds
in-house is a perfect case in point where a firm can accelerate its learning curve by initially
contracting out manufacturing activity. By using CMOs, the firm can obtain access to state of
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the art equipment and expertise in the field. The firm can opt to provide appropriate training for
their staff at the CMO and thus shorten the ramp-up time should they choose to perform the
process in-house in the future. A biopharmaceutical company should consider outsourcing not
only for the principal reason for shortening the time to market but as well as a mechanism to
develop internal expertise that could prove useful in future manufacturing operations.
When making sourcing decisions, one needs to focus on the global long term optimum. At
first glance, outsourcing can appear to be the quickest and cheapest way to market, and may be
hastily chosen as a tactical solution to capacity needs for the relative near-term. However, in
order to achieve a global long term optimum, one needs to look at the strategy of the firm and
assess the market forecasts, projected revenues and margins that would be obtained for
performing the function in-house versus outsourcing.
One should assess the needs of the organization as a whole, rather than the local optimums
at each site. When conducting the research and interviewing personnel to evaluate the make
versus buy decision for encapsulation, it was discovered that the outsourcing decision as well as
the decision of where to perform in-house is largely based on the incentives and interests of the
entity conducting the analysis. Different company divisions or sites had different opinions as to
where encapsulation should be performed. Personnel at different company locations that used
the frameworks to evaluate sourcing options utilized different priorities and weighting factors
which produced varying results. It was found that in order for the frameworks to be used to
achieve a global long term optimum for the corporation, the key decision makers need to utilize
the frameworks with consistent weighting factors and without biases to specific site interests. It
is recommended that a team responsible for corporate operations evaluate the results of the
frameworks so as to ensure a global rather than site specific optimum.
Companies should be cautious when applying a vertical integration strategy that worked
well in one division of the organization to other divisions. Often a corporate strategy,
specifically a vertical integration strategy, is not optimal for all areas of the organization. For
example, in Genzyme's case, the researcher found that Genzyme was eager to vertically integrate
their small molecule and polymer manufacturing facilities because that was their corporate
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strategy and had brought them success in the biologics business. As a company grows into new
areas where the industry dynamics are different, it is important to reevaluate the vertical
integration strategy for the new value chain. For example, in the case study involving high
potency drug manufacturing, outsourcing to a CMO was determined to be better than performing
in-house; this would not have been discovered if Genzyme simply applied its vertical integration
strategy to all areas of the business without careful consideration.
One needs to take into account the overall strategy of the company, i.e. its intent to become
a Fully Integrated Pharmaceutical Company (FIPCO), when assessing make versus buy
decisions. The case studies discussed in this thesis demonstrate the need to align the make
versus buy decision with the strategy of the firm. Genzyme, unlike many biotech firms, has a
strategy of vertical integration, and thus the make versus buy decisions that occur there are quite
different from those at its competitors which elect to outsource to a greater degree. The
researcher determined early on that although industry best practices may lead one to attempt to
convince a firm to outsource, if vertical integration is determined to be the firm's competitive
advantage, than all make versus buy decisions need to be assessed with this in mind.
6.3 FUTURE ACTIVITIES
Genzyme has a strategy of being fully vertically integrated, and has been highly successful in the
biopharmaceutical world. This begs the question of whether or not their vertical integration
strategy has led to their success. The researcher believes that Genzyme has been able to extract
significant margins from producing in-house that they would have otherwise had to share with
contract manufacturers. In addition, Genzyme has cultivated a learning organization enabled by
the continuous improvement efforts that are ongoing at their facilities. However, that is not to
say that Genzyme could not benefit from outsourcing certain functions. In fact, the researcher
believes that Genzyme should carefully evaluate the pipeline of products and assess whether or
not CMOs can produce the drugs cheaper, better, and quicker. Through carefully applying the
frameworks for strategic sourcing, Genzyme may find that they should reevaluate their vertical
integration strategy for certain market segments, such as small molecule and polymer based
drugs. In addition, as CMOs become more proficient with the manufacturing of biologics,
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Genzyme should highly consider qualifying a supplier as a second source in the case of an
accident or disaster at one of their facilities.
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